TY - JOUR
T1 - 1α,25-dihydroxyvitamin D3 increases TGF β1 binding to human osteoblasts
AU - Nagel, David
AU - Kumar, Rajiv
N1 - Funding Information:
Work was supported by NIH Grant DK 25409, DK 58546, and AR 27032.
PY - 2002
Y1 - 2002
N2 - 1β,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) increases the binding of transforming growth factor β1(TGF β1) via TGF β receptors to the surface of human osteoblasts. The increase in TGF β receptors induced by 1α,25(OH)2D3 is dependent on increases in TGF β secretion induced by 1α,25(OH)2D3, since antibodies directed against TGF β block the increase in TGF β1 binding. The increase in TGF β type I and II receptors on cell surfaces following 1α,25(OH)2D3 treatment is associated with increases in receptor mRNA concentrations. Increases in receptor mRNA concentrations following 1α,25(OH)2D3 treatment are not due to changes in receptor gene transcription. The role of TGF β receptors, in mediating the growth responses to 1α,25(OH)2D3 is demonstrated by showing that osteoblasts which express dominant negative, kinase-deficient TGF β type II receptors, fail to respond to the growth-inhibitory effects of 1α,25(OH)2D3. An increase in TGF β receptor expression is important in mediating 1α,25(OH)2D3-associated changes in the growth rate of osteoblasts.
AB - 1β,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) increases the binding of transforming growth factor β1(TGF β1) via TGF β receptors to the surface of human osteoblasts. The increase in TGF β receptors induced by 1α,25(OH)2D3 is dependent on increases in TGF β secretion induced by 1α,25(OH)2D3, since antibodies directed against TGF β block the increase in TGF β1 binding. The increase in TGF β type I and II receptors on cell surfaces following 1α,25(OH)2D3 treatment is associated with increases in receptor mRNA concentrations. Increases in receptor mRNA concentrations following 1α,25(OH)2D3 treatment are not due to changes in receptor gene transcription. The role of TGF β receptors, in mediating the growth responses to 1α,25(OH)2D3 is demonstrated by showing that osteoblasts which express dominant negative, kinase-deficient TGF β type II receptors, fail to respond to the growth-inhibitory effects of 1α,25(OH)2D3. An increase in TGF β receptor expression is important in mediating 1α,25(OH)2D3-associated changes in the growth rate of osteoblasts.
KW - 1α,25-dihydroxyvitamin D
KW - Cellular growth
KW - Osteoblasts
KW - TGF β receptors
KW - Transforming growth factor β
UR - http://www.scopus.com/inward/record.url?scp=0036295959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036295959&partnerID=8YFLogxK
U2 - 10.1006/bbrc.2002.6387
DO - 10.1006/bbrc.2002.6387
M3 - Article
C2 - 11820800
AN - SCOPUS:0036295959
SN - 0006-291X
VL - 290
SP - 1558
EP - 1563
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 5
ER -